research reports and media, page-1885

Let's not forget we are some way behind the original schedule, which in the Baker Young analysis looked like this:


As well the quarterly spend before getting to overlapping trials is already at $10m per quarter. That includes ongoing R&D for other than iPPS-Zilosul (eg MPS). With the current spend rate we will run out of money by 1Q23.
Apparently JP Morgan think there will be revenue of $70m in 2023 (ref @poolboy ). IMO that would most likely be an initial distribution deal rather than iPPS revenue even if Australian TGA approval was obtained by then.
So as i see it we will be needing more cash by late 2022 early 2023, or a deal.
BigPharma can see our cash position because it will be in the 4c.
Holders may need to weigh those possibilities in terms of share price growth until the whole project is fully funded.
PR and co need to shed some light on whole project funding. So that is what we need to be asking.

IMO PAR is still a buy anywhere below $4 (subject to IND approval by FDA and no further delays), except that i am fully invested.
DYOR.
PS: i don't see PAR as having certain revenue from Japan even if ReqMed are only at stage IIa.